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Previous studies have shown decreased in vitro activity of zwitterionic cephalosporins and carbapenems
against porin-deficient Klebsiella pneumoniae expressing a plasmid-mediated AmpC-type -lactamase
(PACBL). The in vitro and in vivo activities of cefepime and imipenem were evaluated against the porin-
deficient strain K. pneumoniae C2 and its CMY-2-producing derivative [K. pneumoniae C2(pMG248)]. The
MICs (in micrograms/milliliter) of cefepime and imipenem against K. pneumoniae C2 were 0.125 and 0.25,
respectively, while the corresponding values against K. pneumoniae C2(pMG248) were 8 and 16. Cefepime
showed a greater inoculum effect than imipenem against both strains. Imipenem showed a significant post-
antibiotic effect (>2 h) against K. pneumoniae C2(pMG248) at 1, 2, 4, 6, and 8 MIC. The maximum
concentrations of drug in serum of cefepime and imipenem in a pneumonia model using mice were 124.1 and
16.9 g/ml, respectively. T/MIC for K. pneumoniae C2 and C2(pMG248) were 1.29 h and 0.34 h for imipenem
and 2.96 h and 1.27 h for cefepime. Both imipenem (30 mg/kg of body weight every 3 h) and cefepime (60 mg/kg
every 4 h), administered for 72 h, increased the survival rate (86.6% and 100%) compared with untreated
control animals (26.6%, P < 0.003) infected with K. pneumoniae C2. For the CMY-2-producing strain, imi-
penem, but not cefepime, increased the survival rate compared to the controls (86.6% and 40% versus 40%, P
< 0.01). Bacterial concentration of the lungs was significantly decreased by both antimicrobials. In conclusion,
imipenem was more active in terms of survival than cefepime for the treatment of murine pneumonia caused
by a porin-deficient K. pneumoniae expressing PACBL CMY-2.
Beta-lactamase production is the most important resistance
mechanism to -lactam antibiotics in gram-negative bacteria.
Initial resistance to expanded-spectrum cephalosporins was
mediated by hyperproduction of chromosomal class C -lacta-
mases in a limited number of species, such as Escherichia coli,
Enterobacter spp., Serratia marcescens, Citrobacter freundii, and
Pseudomonas aeruginosa (18, 30). In those bacteria unable to
produce AmpC (K. pneumoniae, Proteus mirabilis, Salmonella
spp.), resistance to expanded-spectrum cephalosporins was
mediated by extended-spectrum -lactamases (ESBL) belong-
ing to the TEM, SHV, or CTX-M types (13, 14, 15, 31). These
ESBLs were active against oxyimino-cephalosporins but not
against 7--metoxy-cephalosporins, -lactamase inhibitors, or
carbapenems (13, 14, 18).
The continued use of cephamycins and combinations of
-lactam–-lactamase inhibitors are potential contributors to
the appearance of plasmids which encode class C -lactamases
(PACBL) in K. pneumoniae, Escherichia coli, and, to a lesser
extent, other enterobacteria (22). These enzymes are not in-
activated by clinically used -lactamase inhibitors and confer a
spectrum of activity greater than that observed in ESBLs.
Since the first description of MIR-1 and CMY-1, more than
20 PACBLs have been described in different countries of Eu-
rope, America, and Asia, most of them being discovered in K.
pneumoniae strains (4, 26). CMY-2 is one of the most prevalent
and most widely distributed PACBLs and has been found in
several countries (27). Taking into consideration the difficulty
of detecting PACBLs, the real prevalence of these enzymes is
probably underestimated. In one United States study which
included 25 states, PACBLs were found in 8.5%, 6.9%, and 4%
of K. pneumoniae, K. oxytoca, and E. coli, respectively (1).
Strains expressing PACBL are consistently resistant to pen-
icillins, oxyimino-cephalosporins, and cephamycins. Most of
them are also resistant to aztreonam and -lactamase inhibitor
combinations, with the occasional exception of piperacillin-
tazobactam (27). Nevertheless, susceptibility to cefepime, cef-
pirome, and carbapenems was not affected by these enzymes
(27).
Loss of outer membrane porins in PACBL expressing K.
pneumoniae can increase the MICs of carbapenems to the
resistant category (20). Moreover, in such strains, the MICs of
cefepime and cefpirome show inoculum dependence exceeding
values of 256 g/ml at an inoculum of 107 CFU/ml (12). Clin-
ical strains of both K. pneumoniae and E. coli, whose imipenem
MICs are as high as 64 g/ml owing to porin loss and PACBLs
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(CMY-4, ACT-1), have been described already (5, 6, 33). The
potential use of zwitterionic cephalosporins (i.e., cefepime and
cefpirome) and carbapenems in infections caused by strains
expressing both resistance mechanisms is currently unknown.
The purpose of this study is to compare the use of cefepime
and imipenem in a murine pneumonia model caused by
PACBL (CMY-2)-expressing K. pneumoniae and lacking major
porins.
MATERIALS AND METHODS
Bacterial strains. K. pneumoniae C2 is a previously described (20, 21) cefta-
zidime-susceptible strain, derived in vitro from the clinical isolate K. pneumoniae
NEDH-1 (deficient in porins OmpK35 and OmpK36 and producing SHV-2). K.
pneumoniae C2(pMG248) is a transconjugant derived from K. pneumoniae C2,
containing the plasmid pMG248, which codes for PACBL CMY-2 (1). Plasmid
pMG248 was introduced into K. pneumoniae C2 by conjugation, as previously
described (20). K. pneumoniae C2(pMG248) does not lose pMG248 upon re-
peated subculturing in an antimicrobial-free medium (data not shown).
Antimicrobial agents. Imipenem and imipenem plus cilastatin were obtained
from Merck and Sharp and Dohme (Madrid, Spain) for the in vitro and the in
vivo experiments, respectively, and cefepime was from Bristol-Myers Squibb
(Madrid, Spain).
Susceptibility testing and time-kill curve experiments. MICs of cefepime and
imipenem against K. pneumoniae strains C2 and C2(pMG248) were determined
by microdilution according to NCCLS guidelines (24). The activities of the three
-lactams were tested using three different inocula: 105, 106, and 107 CFU/ml.
Minimal bacterial concentrations (MBCs) were determined by subculturing onto
antimicrobial-free Mueller-Hinton agar (MHA) 100-l aliquots of wells contain-
ing antimicrobial concentrations greater than or equal to the MIC of the corre-
sponding agent. Plates were incubated at 35°C for 48 h, and viable colonies were
counted. MBCs were determined as the concentration that killed 99.9% of the
initial inoculum.
Time-kill kinetic assays were conducted on the Mueller-Hinton broth (MHB)
at drug concentrations of 1 and 4 MIC. A control without using antibiotics
was evaluated in parallel. The starting inoculum was 106 CFU/ml. Cultures were
incubated at 37°C, without shaking. Viable counts were determined by serial
dilution at 0 h, 2 h, 4 h, 8 h, and 24 h after adding the drug. Viable counts were
determined by plating 100 l of control or test cultures at the indicated times
onto MHA plates. Plates were incubated for 48 h, and the colony count, the log10
of viable cells (CFU/ml), was determined.
Determination of postantibiotic effect (PAE) of imipenem and cefepime. The
in vitro PAE of imipenem and cefepime was investigated for both strains [K.
pneumoniae C2 and C2(pMG248)] by exposing the bacteria (107 CFU/ml) to the
drug at a concentration of equal to 1, 2, 4, 6, and 8 MIC for 1.5 h (19).
The antibiotic was removed from the culture by three centrifugations and resus-
pended in fresh MHB. The antibiotic-free bacterial resuspension was then incu-
bated at 37°C and shaken. After removal of the drug, viable counts were per-
formed hourly for the next 8 h. A growth control, prepared and treated in a
similar way to the test solution but without being exposed to antibiotics, was
included in each experiment. The PAE was calculated as previously described
(7).
Animals. Immunocompetent C57BL/6 female mice weighing 14 to 16 g were
used. They were obtained from the University of Seville’s facility, had a sanitary
status of MPF (murine pathogen free), and were assessed for genetic authentic-
ity. Animals were housed in regulation cages and given free access to food and
water.
Drug pharmacokinetics. The plasma levels of imipenem and cefepime were
determined after administration of a single intramuscular (i.m.) dose of each
antimicrobial. The dosage administered was 30 mg/kg of body weight for imi-
penem and 60 mg/kg for cefepime. After 10, 15, 30, 60, 90, 120, and 150 min,
blood was extracted from the periorbital plexus of three anesthetized mice per
time point. The total plasmatic drug concentrations were measured by the bio-
assay method, using Micrococcus luteus ATCC 9341 as the indicator strain. The
intraday and interday variations of the assays were 3.43%  0.75% and 4.48% 
2.42% for cefepime and 2.62%  2.44% and 3.22%  1.91% for imipenem; the
linearity (r2) of the assay was 0.96  0.69 and 0.91  0.02, respectively; the lower
limits of detection were 0.9 and 0.01 g/ml. The maximum plasma concentration
(Cmax, in milligrams per liter) and terminal half-life (t1/2, in hours) were calcu-
lated using the PKCALC program (32). The time during which the plasma
concentration remained above the MIC (T/MIC, in hours) was estimated by
extrapolation from the regression line of plasma elimination (9) using the MIC
obtained with an inoculum of 105 CFU/ml.
Experimental pneumonia model in mice. A modification of the Esposito and
Pennington model (8) performed by our group (29) was used to produce pneu-
monia. The mice were anesthetized with an intraperitoneal (i.p.) injection of 5%
sodium thiopental. They were suspended vertically, and the tracheae were then
cannulated with a blunt-tipped metal needle. The feel of the needle tip against
the tracheal cartilage confirmed the intratracheal location. A microliter syringe
(Hamilton Co., Reno, NV) was used for the inoculation. After inoculation, the
mice remained in a vertical position for 3 min and then in a 30° position until they
awoke.
Klebsiella pneumoniae C2 and C2(pMG248) were used in the experimental
pneumonia. The animals were inoculated with 50 l of the K. pneumoniae
bacterial suspension, obtained through an 18-h culture in trypticase soy broth
(Becton-Dickinson Microbiology Systems) at 37°C and mixed 1:1 with porcine
mucin diluted to 10% in saline solution (M-2378; Sigma Chemical Co., St. Louis,
MO), with a final inoculum size of approximately 108 CFU/ml.
Antimicrobial treatment. To evaluate the effectiveness of the different treat-
ment regimens, 50 mice were inoculated with the C2 strain and 50 mice were
inoculated with the C2(pMG248) strain. They were then divided into three
groups, which received the following treatments for 72 h: control (not treated, n
 20); imipenem, 30 mg/kg every 3 h, i.m. (n  15); and cefepime, 60 mg/kg every
4 h, i.m. (n  15); the doses of imipenem and cefepime were chosen to obtain a
T/MIC referring to K. pneumoniae C2 which was higher than 40% of the dosing
interval. The first dose of every antibiotic was administered 4 h after inoculation
with the following dose schedule: 30 mg/kg every 3 h for imipenem and 60 mg/kg
every 4 h for cefepime. The animals were observed for 72 h for mortality, and
surviving mice were killed 4 h after the last dose by i.p. administration of 5%
sodium thiopental (Braun Medical, Barcelona, Spain). All the mice were ana-
lyzed immediately after death. Once the animals were dead, thoracotomy was
carried out. The heart and lungs were extracted together, and the lungs were
later separated onto a sterile petri plate and weighed. The lungs were processed
for quantitative culture after being homogenized in 2 ml of sterile saline solution
(Stomacher 80 Tekmar Co., Cincinnati, Ohio). After 10-fold dilution, aliquots of
100 l were plated onto Columbia sheep-blood agar plates for 24 h at 37°C.
Sterile cultures were considered to have 1 log CFU/g of lung. The results were
expressed as the means  standard deviations of the log CFU/gram of the lung.
Lung samples were processed for histological study in five mice from each
control group. The lungs were fixed with 10% formaldehyde for pathological
study. The lung blocks were embedded in paraffin and cut into 4-m-thick sections.
The slices included all the pulmonary lobes to be studied by optical microscopy. They
were processed according to standard methods for hematoxylin-eosin, periodic acid-
Schiff, Gram, Masson’s Trichromic, and silver reticulin stains.
In order to confirm that imipenem and cefepime were not toxic to the animals,
groups of 10 noninfected mice were each given the antibiotics for 72 h.
The use of the experimental pneumonia model was approved by the Ethics
Committee of the Hospitales Universitarios Virgen del Rocı́o, Seville, Spain.
Selection and characterization of antimicrobial-resistant mutants. Selection
of mutants derived from either K. pneumoniae C2 or C2(pMG248) was per-
formed by inoculating the lung homogenates in either medium containing 4
MIC of cefepime or imipenem against the tested strain. Lungs from 15 animals
treated with cefepime or imipenem were used in these assays. Plates were
incubated at 35°C for 48 h, and the colonies were counted. In a parallel exper-
iment, mutants were also selected under the same conditions, using a suspension
of bacteria grown in trypticase soy broth (35°C, 20 h) as an inoculum. Frequency
of mutation was expressed as the ratio between the number of colonies on plates
containing 4 MIC of the corresponding agent and the original inoculum. Up to
eight different colonies on every plate were selected for further study. Bacteria
were subcultured twice on antimicrobial agent-free Mueller-Hinton agar. The
activity of cefepime or imipenem by disk diffusion (25) was determined for every
colony. True mutants were defined as those whose inhibition diameter around
cefepime (30 g; Oxoid) or imipenem (10 g) decreased to 10 mm.
Statistical analysis. Numbers of surviving animals were evaluated with the
Fisher’s exact test. The CFU/gram of lung tissue was analyzed using the homo-
geneity of variance and posthoc tests (Tukey-Kramer and Dunnet test). The
SPSS 11.5 statistical package (SPSS Inc., Chicago, IL) was used. A P value of
	0.05 was considered significant.
RESULTS
In vitro studies. MICs and MBCs of cefepime and imipenem
against K. pneumoniae C2 and K. pneumoniae C2(pMG248)
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containing the blaCMY-2 gene are shown in Table 1. For both
strains, imipenem showed a lower inoculum effect than
cefepime, but these differences were not significant for the
CMY-2-producing strain. The results of time-kill curve exper-
iments with cefepime and imipenem were the following. First,
against K. pneumoniae C2, imipenem showed a higher bacteri-
cidal effect than did cefepime. Bacterial regrowth was observed
for 1 MIC of cefepime and imipenem at 4 and 8 h, respectively.
Second, imipenem produced a rapid bactericidal effect against K.
pneumoniae C2(pMG248) at both 1 and 4 MIC. After 24 h,
regrowth was not noted. Cefepime produced a lower bactericidal
effect than imipenem against this strain, and bacterial regrowth
was observed after 4 to 8 h of incubation. Against this strain, the
time required to obtain a 3 log reduction of the initial inoculum
was 8 h for cefepime and 2 h for imipenem.
In vitro determination of PAE. After exposure for 1.5 h,
imipenem at 1, 2, 4, 6, and 8 MIC showed a PAE
against K. pneumoniae C2(pMG248) of 2 h when compared to
control cultures without antimicrobial agents (Fig. 1). PAE was
not observed with imipenem against K. pneumoniae C2.
Cefepime did not show any PAE against either K. pneumoniae
C2 or C2(pMG248).
Pharmacokinetic studies. The pharmacokinetic and phar-
macodynamic parameters of each antimicrobial drug used in
the mice (Cmax, t1/2, and T/MIC) are shown in Table 2. The
T/MICs of imipenem and cefepime for the C2 strain were
more than 40% of the interval between doses.
FIG. 1. PAE of imipenem and cefepime against K. pneumoniae C2(pMG248) after 1.5 h of exposure to 1, 2, 4, 6, and 8 MIC of
cefepime (FEP) and imipenem (IPM).
TABLE 1. MICs and MBCs of cefepime and imipenem against two






C2 Imipenem 105 0.25 0.25
106 0.5 0.5
107 1 1
Cefepime 105 0.125 0.25
106 0.125 0.125
107 4 8
C2(pMG248) Imipenem 105 16 16
106 32 32
107 32 32
Cefepime 105 8 16
106 16 16
107 32 32
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Pathological studies. The mice groups inoculated with
strains C2 and C2(pMG248) showed alterations compatible
with acute pneumonia. They presented acute inflammation,
characterized by diffuse and/or focal affectation of all lobes,
with a mild to severe inflammatory infiltration of polymorpho-
nuclear cells, sometimes forming segmentary abscesses, and
with mild to moderate infiltration of alveolar macrophages.
Gram-negative bacterial colonies and alveolar hemorrhagic
areas were also observed.
Therapeutic efficacy in experimental pneumonia. The sur-
vival rate of each group of mice at 72 h is shown in Table 3.
Survival rates in the control groups were 26.7% (95% inhibi-
tory concentration [IC95], 4.3 to 49.1) and 40% (IC95, 15.2 to
64.8) for strains C2 and C2(pMG248), respectively. In the
treated groups, the survival rates of animals infected with
strain C2 were 86.6% (IC95, 69.4 to 100) for imipenem and
100% for cefepime. The two treatment groups showed an
improved survival rate when compared with the control group
(P 	 0.003), with no difference between either antimicrobial.
For strain C2(pMG248), the survival rates were 86.6% (IC95,
69.4 to 100) for imipenem and 40% (IC95, 15.2 to 64.8) for
cefepime. Imipenem was the only therapy that significantly
decreased the mortality rate when compared with both the
control group and the group treated with cefepime (P 	 0.01).
Bacterial counts found in the lungs of the different groups
are shown in Table 3 and Fig. 2. For K. pneumoniae C2,
cefepime and imipenem significantly cleared the bacteria from
the lungs when compared with the control group (1.74  0.75
and 3.38  1.06 versus 9.16  2.16 CFU/g, P 	 0.01), with
cefepime being the most active agent (P 	 0.001). For CMY-2
producing K. pneumoniae C2(pMG248), both agents showed
significant clearance of bacteria, reducing lung bacterial counts
when compared with the controls (4.33  1.65 for cefepime
and 4.06  1.20 for imipenem versus 9.07  2.75 log CFU/g for
controls, P 	 0.001).
There was no difference between either group treated with
imipenem when survival rates and bacterial clearance from the
lungs were compared. Survival with cefepime was higher in the
group infected with K. pneumoniae C2 than in that infected
with K. pneumoniae C2(pMG248) (P 	 0.0001). In the same
way, bacterial clearance was better with cefepime in the K.
pneumoniae C2 group when compared with K. pneumoniae
C2(pMG248) (P 	 0.01).
Selection of resistant mutants. When lung homogenates
from 15 mice infected with K. pneumoniae C2 and treated with
cefepime or imipenem were used for selection of resistant
mutants, there were no colonies recovered on plates containing
4 MIC. No bacterial growth was obtained from any lung
homogenate of the 15 animals treated with imipenem and
infected with K. pneumoniae C2(pMG248). For the group
treated with cefepime, mutants appeared at a frequency of
10
2 to 10
3 in 5 of the 15 animals. When disk diffusion assay
was used to evaluate the activity of cefepime against these
mutants, zone diameter decreased from 16 mm (in the parental
strain) to 6 mm for all strains tested.
When MHB-grown K. pneumoniae C2 was used for selection
of resistant mutants, frequency of mutation was 5  10
7 and
3.5  10
7 for imipenem and cefepime, respectively. When K.
pneumoniae C2(pMG248) was used, no mutants were detected
for imipenem, although a frequency of mutation of 2  10
5
was observed for cefepime. Twenty independent colonies were
FIG. 2. Effect of antibiotic therapy on the clearance of K. pneu-
moniae from mice lungs.
TABLE 2. Cmax and t1/2 after a single dose of cefepime and
imipenem and T/MIC of both agents for two strains
of K. pneumoniae
Drug (dose) Cmax(mg/liter) t1/2 (h)
T/MIC (h) for strain:
C2 C2(pMG248)
Imipenem (30 mg/kg) 16.9 0.15 1.29 0.34
Cefepime (60 mg/kg) 124.06 0.28 2.96 1.27
TABLE 3. Effect of antibiotic therapy on the survival and clearance of K. pneumoniae from mouse lungs
Treatment Dosage
K. pneumoniae C2 K. pneumoniae C2(pMG248)
n Survival(%) Log CFU/g of lung n
Survival
(%) Log CFU/g of lung
Control 15 4 (26.7) 9.16  2.16 15 6 (40) 9.07  2.75
Imipenem 30 mg/kg every 3 h 15 13 (86.6)a 3.38  1.06a 15 13 (86.6)a 4.06  1.20a
Cefepime 60 mg/kg every 4 h 15 15 (100)a 1.74  0.75a,b 15 6 (40)a,b 4.33  1.65a
a P 	 0.01 compared with the control group.
b P 	 0.01 compared to imipenem.
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selected from individual plates with bacterial growth, as previ-
ously indicated, but in all cases zone diameters were equal to
parental strains. This indicated that none of the chosen colo-
nies contained true (as herein defined) antibiotic-resistant mu-
tants.
DISCUSSION
PACBLs are particularly frequent in K. pneumoniae and K.
oxytoca strains isolated in the hospital setting, although they
have also been detected in other enterobacteria (1, 5, 6, 10, 11,
12, 26, 27). K. pneumoniae strains expressing PACBL are usu-
ally susceptible in vitro to zwitterionic cephalosporins and car-
bapenems, unless other mechanisms of resistance coincide (5,
6, 20, 33, 17, 23). This may be related to the increased stability
of such compounds with respect to AmpC-type beta-lactama-
ses and their excellent penetration through the outer mem-
brane (18, 20). Recently, carbapenem-resistant K. pneumoniae
isolates have been described whose resistance was attributed to
the lack of an outer membrane protein in combination with
PACBL ACT-1 and CMY-4 (5, 6, 33). In some PACBL-pro-
ducing K. pneumoniae strains which lack major porins,
cefepime was active, although a marked inoculum effect was
observed (20). CMY-2 is one of the most prevalent PACBLs
(27). Strains expressing this enzyme are usually susceptible to
both cefepime and imipenem.
In the present study, when CMY-2 was expressed in K.
pneumoniae deficient in the two major porins (OmpK35 and
OmpK36), the strain became resistant to imipenem and an
important increase in the cefepime MIC was observed. At a
high inoculum, K. pneumoniae C2(pMG248) became resistant
to both agents, although the effect was slightly more pro-
nounced for cefepime. The in vivo efficacy of cefepime and
imipenem against CMY-2 producing K. pneumoniae deficient
in major porins is currently unknown. To answer this question,
a pneumonia model using mice was chosen in the present study
because of its resemblance to the pathogenesis of pneumonia
in human beings (8). The pathological findings in the model
confirmed that animals developed pneumonia independently
of CMY-2 expression. The bacterial counts of control animals
were significantly higher than those obtained for treated ani-
mals, permitting evaluation of the therapeutic value of the two
-lactams tested in this study. For the animal model, doses of
30 mg/kg every 3 h and 60 mg/kg every 4 h were chosen for
imipenem and cefepime, respectively, in order to obtain a
T/MIC against K. pneumoniae C2 higher than 40% of the
dosing interval with both antibiotics. Both -lactams tested
showed in vivo activity against K. pneumoniae C2, as inferred
from the significantly higher survival rates and the lower lung
bacterial counts in treated mice when compared to controls.
The two treatment groups showed a similar improved survival
rate when compared to the control group. On the other hand,
in terms of lung bacterial count, while both antibiotics de-
creased the bacterial lung concentration with respect to the
untreated mice, cefepime clearance was significantly greater
than that of imipenem. Although time above MIC was 40%
of the dosing interval for both antibiotics, it was 74% for
cefepime and 43% for imipenem, which may explain this dif-
ference.
When animals infected with the CMY-2-producing strain
were used, the survival rate was significantly greater for imi-
penem than for cefepime, and survival with the latter agent did
not increase in comparison to that obtained in the controls.
The cefepime results for animals infected with the CMY-2-
producing strain were worse than those obtained for animals
infected with the parental strain lacking this beta-lactamase,
although lung bacterial counts in animals subjected to both
treatments were similar (and lower than those of the controls),
while time above MIC was 11.3% and 31.7% for imipenem and
cefepime, respectively. We don’t think there is any discrepancy
between the results of cefepime in terms of survival or bacterial
clearance because, in both variables, cefepime showed less
therapeutic effect against C2(pMG248) than against the C2
strain. It seems, therefore, that, in this model, survival is a
more sensitive end point than bacterial clearance from the
lungs. We think that the poor results in terms of survival with
cefepime, in the group infected by the C2(pMG248) strain, is
due to the lower bactericidal activity of this agent and for its
capability to induce the appearance of resistant mutants; more-
over, the low survival in this group may not be a consequence
of endotoxin release, because of the high survival in the group
infected with the C2 strain in which the bactericidal in vivo
activity was higher. The in vivo activity of imipenem, however,
was similar against both strains in terms of survival rate and
bacterial clearance of the lung, which may be explained by
several factors discussed below.
The in vitro data of the activity of cefepime and imipenem
support these in vivo results and expand our previous (20)
observations. The MICs indicate good activity of both
cefepime and imipenem against K. pneumoniae C2. Both
agents, however, showed reduced activity (particularly using
high inocula) against the CMY-2 producing transconjugant,
with the inoculum effect being slightly more pronounced for
cefepime. Time-kill studies also supported these findings.
Cefepime was less bactericidal than imipenem. Bacterial re-
growth was observed at 8 h incubation with 1 MIC of
cefepime for the CMY-2-producing strain. This regrowth was
not observed for imipenem even after 24 h of incubation. The
clinical significance of bacterial regrowth is currently unclear
but reinforces the importance of an adequate cefepime admin-
istration schedule for maintaining concentrations which are
above the MIC between dosage intervals (2). Finally, imi-
penem, but not cefepime, showed a PAE effect against CMY-
2-producing K. pneumoniae. It was surprising that imipenem
did not show any PAE effect against the parental K. pneu-
moniae C2 strain. Although we do not have a precise explana-
tion for this finding, it could related, at least in part, to the fact
that PAE was calculated as a function of the MIC of imipenem
for either K. pneumoniae C2 or its CMY-2-producing deriva-
tive, and for this reason the absolute amounts of imipenem
were much higher for the CMY-2-producing strain.
An additional explanation for therapy failure with antimi-
crobial agents might be the emergence of resistant mutants.
We used two different approaches for mutant selection and, in
general, similar results were obtained with both methods. Al-
though bacterial growth was noted on plates containing 4
MIC of cefepime (both strains) and imipenem (CMY-2-pro-
ducing strain), the only true mutants were isolated by cefepime
from the in vivo grown K. pneumoniae C2(pMG248). In the
other cases, the organisms were not actual mutants, and it is
VOL. 49, 2005 THERAPY FOR K. PNEUMONIAE PRODUCING CMY-2 3315


























possible that they represent organisms able to survive the bac-
tericidal activity of cefepime by mechanisms yet to be deter-
mined (16). The genetic basis of the truly cefepime-resistant
mutants is not known at this moment, but preliminary results
indicate that they are overproducers of -lactamase. Further
studies on this matter and on the possible clinical relevance of
these mutants are in progress.
In summary, both in vitro and in vivo results obtained from
this study indicate that, in terms of animal survival, imipenem
is superior to cefepime in the treatment of murine pneumonia
caused by a porin-deficient K. pneumoniae expressing CMY-2.
Furthermore, it has been shown that CMY-2 should be more
able than other -lactamases to develop the ability to confer
higher levels of cefepime resistance (3), which might endanger
the future use of this agent in infections caused by CMY-2-
producing bacteria.
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para la Investigación en Patologı́a Infecciosa (REIPI-ISCIII-C03/14),
Spain.
REFERENCES
1. Alvarez, M., J. H. Tran, N. Chow, and G. A. Jacoby. 2004. Epidemiology of
conjugative plasmid-mediated AmpC beta-lactamases in the United States.
Antimicrob. Agents Chemother. 48:533–537.
2. Barbhaiya, R. H., S. T. Forgue, and C. R. Gleason. 1992. Pharmacokinetics
of cefepime after single and multiple intravenous administrations in healthy
subjects. Antimicrob. Agents Chemother. 36:552–557.
3. Barlow, M., and B. G. Hall. 2003. Experimental prediction of evolution of
cefepime resistance from the CMY-2 AmpC -lactamase. Genetics 164:23–
29.
4. Bauernfeind, A., Y. Chong, and S. Schweighart. 1989. Extended broad spec-
trum -lactamase in Klebsiella pneumoniae including resistance to cephamy-
cins. Infection 17:316–321.
5. Bradford, P. A., C. Urban, N. Mariano, S. J. Projan, J. J. Rahal, and K.
Bush. 1997. Imipenem resistance in Klebsiella pneumoniae is associated with
the combination of ACT-1, a plasmid-mediated AmpC -lactamase, and the
loss of an outer membrane protein. Antimicrob. Agents Chemother. 41:563–
569.
6. Cao, V. T., G. Arlet, B. M. Ericsson, A. Tammelin, P. Courvalin, and T.
Lambert. 2000. Emergence of imipenem resistance in Klebsiella pneumoniae
owing to combination of plasmid-mediated CMY-4 and permeability alter-
ation. J. Antimicrob. Chemother. 46:895–900.
7. Craig, W. A., and S. Gudmunsson. 1991. Postantibiotic effect, p. 403–431. In
V. Lorian (ed.), Antibiotics in medicine, 3rd ed. Williams and Wilkins,
Baltimore, Md.
8. Esposito, A. L., and J. E. Pennington. 1983. Effect of aging on antibacterial
mechanisms in experimental pneumonia. Am. Rev. Respir. Dis. 128:662–
667.
9. Fridmodt-Moller, N., M. W. Bentzon, and V. F. Thomsen. 1986. Experimen-
tal infection with Streptococcus pneumoniae in mice: correlation of in vitro
activity and pharmacokinetic parameters with in vivo effect for 14 cephalo-
sporins. J. Infect. Dis. 154:511–517.
10. Gazouli, M., L. S. Tzouvelekis, E. Prinarakis, V. Miriagou, and E. Tzelepi.
1996. Transferable cefoxitin resistance in enterobacteria from Greek hospi-
tals and characterization of a plasmid-mediated group 1 -lactamase (LAT-
2). Antimicrob. Agents Chemother. 40:1736–1740.
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